tiprankstipranks
Advertisement
Advertisement
Monte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51
PremiumThe FlyMonte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51
2M ago
Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
Premium
The Fly
Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
2M ago
GLUE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
GLUE Earnings this Week: How Will it Perform?
2M ago
Monte Rosa Therapeutics 11.125M share Secondary priced at $24.00
PremiumThe FlyMonte Rosa Therapeutics 11.125M share Secondary priced at $24.00
4M ago
Monte Rosa Therapeutics Ends Current ATM Equity Program
Premium
Company Announcements
Monte Rosa Therapeutics Ends Current ATM Equity Program
4M ago
Monte Rosa Therapeutics announces $200M common stock offering
Premium
The Fly
Monte Rosa Therapeutics announces $200M common stock offering
4M ago
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
PremiumThe FlyMonte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
4M ago
Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today
Premium
Market News
Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today
4M ago
Monte Rosa Therapeutics: Early MRT-8102 hsCRP Data Underscore Differentiated NLRP3 Opportunity and Attractive Risk-Reward Supporting Buy Rating
Premium
Ratings
Monte Rosa Therapeutics: Early MRT-8102 hsCRP Data Underscore Differentiated NLRP3 Opportunity and Attractive Risk-Reward Supporting Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100